Loading...

Danielle Schlosser, PhD

Title(s)Assistant Professor, Psychiatry
SchoolSchool of Medicine
Address401 Parnassus Ave.
San Francisco CA 94143
Phone415-476-8721
ORCID ORCID Icon0000-0001-7652-0924 Additional info
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Biography 
    Collapse Awards and Honors
    NIH/NIMH 2013  - 2018Career Development Award (K23 MH097795)
    NIH/NIMH2013  - 2016Clinical Trial Planning Award (R34 MH100399)
    UCSF, CTSI2014  - 2015Digital Health Research Award
    UCSF, CTSI2013  - 2014Catalyst Award in Digital Health
    UCSF, CTSI2012  - 2013Mobile Health Research Award

    Collapse Overview 
    Collapse Overview
    Dr. Schlosser currently holds the positions of Assistant Professor in the Department of Psychiatry at the University of California, San Francisco, Director of the Digital Health Core in the Department of Psychiatry, and Director of the NIH-funded Digital Research and Interventions for Volitional Enhancement (DRIVE) lab. The goal of her research program is to design, develop, and investigate neuroscience-informed digital health solutions to improve the lives of people with schizophrenia and depression. She has a broad background in clinical psychology, with specific training in behavioral neuroscience, early detection and intervention of psychosis, and digital health research. Dr. Schlosser's research is focused on translating the latest findings in the area of reward processing and psychological determinants of motivation into new interventions to treat individuals with schizophrenia and depression. Her focus in on targeting domains that transcend diagnostic labels, such as motivational states and enhancing outcomes, such as quality of life. More recently, with funding from NIMH, her research was focused on developing a mobile app called PRIME, which was designed to target the motivational system and thereby enhance the drive to improve one's quality of life and health outcomes. Her lab is testing the feasibility and impact of PRIME in two ongoing clinical trials in schizophrenia and they recently completed a pilot trial in depression. Two of the three trials were conducted entirely remotely, one with individuals with depression and the other with individuals recently diagnosed with schizophrenia.

    Collapse Research 
    Collapse Research Activities and Funding
    Scaling a smarter and more efficient intervention: Evaluating the feasibility of disseminating a novel mobile app platform to treat depression
    NIH/NIMH R34MH110583Aug 1, 2016 - Oct 31, 2018
    Role: Principal Investigator
    Enhancing Functional Outcomes in Schizophrenia Using a Novel mHealth Approach
    NIH/NIMH R34MH100399Aug 1, 2013 - May 31, 2016
    Role: Co-Principal Investigator
    PRIME to Action: Enhancing Motivation in Recent Onset Schizophrenia
    NIH/NIMH K23MH097795May 3, 2013 - Apr 30, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. 146. The Malleability of Social Motivation in Recent-Onset Schizophrenia. Biological Psychiatry. 2019 May 1; 85(10):s61. Tim Campellone, Danielle Schlosser. .
      View in: Publisher Site   Mentions:
    2. Measuring The Lifetime Costs Of Serious Mental Illness And The Mitigating Effects Of Educational Attainment. Health Aff (Millwood). 2019 04; 38(4):652-659. Seabury SA, Axeen S, Pauley G, Tysinger B, Schlosser D, Hernandez JB, Heun-Johnson H, Zhao H, Goldman DP. PMID: 30933598.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    3. Development and testing of a web-based battery to remotely assess cognitive health in individuals with schizophrenia. Schizophr Res. 2019 06; 208:250-257. Biagianti B, Fisher M, Brandrett B, Schlosser D, Loewy R, Nahum M, Vinogradov S. PMID: 30733167.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    4. Efficacy of PRIME, a Mobile App Intervention Designed to Improve Motivation in Young People With Schizophrenia. Schizophr Bull. 2018 08 20; 44(5):1010-1020. Schlosser DA, Campellone TR, Truong B, Etter K, Vergani S, Komaiko K, Vinogradov S. PMID: 29939367.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    5. Childhood trauma and clinical high risk for psychosis. Schizophr Res. 2019 03; 205:10-14. Loewy RL, Corey S, Amirfathi F, Dabit S, Fulford D, Pearson R, Hua JPY, Schlosser D, Stuart BK, Mathalon DH, Vinogradov S. PMID: 29779964.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. Psychiatr Serv. 2018 05 01; 69(5):590-592. Baumel A, Baker J, Birnbaum ML, Christensen H, De Choudhury M, Mohr DC, Muench F, Schlosser D, Titov N, Kane JM. PMID: 29334875.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Social motivation in people with recent-onset schizophrenia spectrum disorders. J Psychiatr Res. 2018 04; 99:96-103. Campellone TR, Truong B, Gard D, Schlosser DA. PMID: 29428842.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Potential Benefits of Incorporating Peer-to-Peer Interactions Into Digital Interventions for Psychotic Disorders: A Systematic Review. Psychiatr Serv. 2018 04 01; 69(4):377-388. Biagianti B, Quraishi SH, Schlosser DA. PMID: 29241435.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    9. The feasibility, acceptability, and outcomes of PRIME-D: A novel mobile intervention treatment for depression. Depress Anxiety. 2017 06; 34(6):546-554. Schlosser DA, Campellone TR, Truong B, Anguera JA, Vergani S, Vinogradov S, Arean P. PMID: 28419621.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    10. SU133. CLIMB: A Mobile Intervention to Enhance Social Functioning in People With Psychotic Disorders: Results From a Feasibility Study. Schizophrenia Bulletin. 2017 Mar 1; 43(suppl_1):s210-s210. Bruno Biagianti, Danielle Schlosser, Mor Nahum, Josh Woolley, Sophia Vinogradov. .
      View in: Publisher Site   Mentions:
    11. 189. Trauma, Stress Mechanisms, and Risk for Psychosis. Schizophrenia Bulletin. 2017 Mar 1; 43(suppl_1):s99-s99. Rachel Loewy, Sarah Corey, Seghel Yohannes, Felix Amirfathi, Rahel Pearson, Sawsan Dabit, Daniel Fulford, Barbara Stuart, Danielle Schlosser, Daniel Mathalon, Elissa Epel, Owen Wolkowitz, Sophia Vinogradov. .
      View in: Publisher Site   Mentions:
    12. Creating Live Interactions to Mitigate Barriers (CLIMB): A Mobile Intervention to Improve Social Functioning in People With Chronic Psychotic Disorders. JMIR Ment Health. 2016 Dec 13; 3(4):e52. Biagianti B, Schlosser D, Nahum M, Woolley J, Vinogradov S. PMID: 27965190.
      View in: PubMed   Mentions:
    13. Feasibility of PRIME: A Cognitive Neuroscience-Informed Mobile App Intervention to Enhance Motivated Behavior and Improve Quality of Life in Recent Onset Schizophrenia. JMIR Res Protoc. 2016 Apr 28; 5(2):e77. Schlosser D, Campellone T, Kim D, Truong B, Vergani S, Ward C, Vinogradov S. PMID: 27125771.
      View in: PubMed   Mentions:
    14. Intensive Auditory Cognitive Training Improves Verbal Memory in Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophr Bull. 2016 07; 42 Suppl 1:S118-26. Loewy R, Fisher M, Schlosser DA, Biagianti B, Stuart B, Mathalon DH, Vinogradov S. PMID: 26903238.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    15. Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis. Schizophr Res. 2015 Dec; 169(1-3):204-208. Schlosser DA, Campellone TR, Biagianti B, Delucchi KL, Gard DE, Fulford D, Stuart BK, Fisher M, Loewy RL, Vinogradov S. PMID: 26530628.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. Motivational deficits in individuals at-risk for psychosis and across the course of schizophrenia. Schizophr Res. 2014 Sep; 158(1-3):52-7. Schlosser DA, Fisher M, Gard D, Fulford D, Loewy RL, Vinogradov S. PMID: 25008792.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    17. Family-Focused Treatment for Adolescents and Young Adults at High Risk for Psychosis: Results of a Randomized Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2014. David J. Miklowitz, Mary P. O’Brien, Danielle A. Schlosser, Jean Addington, Kristin A. Candan, Catherine Marshall, Isabel Domingues, Barbara C. Walsh, Jamie L. Zinberg, Sandra D. De Silva, Michelle Friedman-Yakoobian, Tyrone D. Cannon .
    18. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug; 53(8):848-58. Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, Domingues I, Walsh BC, Zinberg JL, De Silva SD, Friedman-Yakoobian M, Cannon TD. PMID: 25062592.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    19. Poster #T207 A NOVEL DIGITAL HEALTH APPROACH TO TREATING NEGATIVE SYMPTOMS USING A PERSONALIZED REAL-TIME INTERVENTION FOR MOTIVATIONAL ENHANCEMENT (PRIME). Schizophrenia Research. 2014 Apr 1; 153:s362. Danielle Schlosser, Silvia Vergani, Daniel Kim, Tim Campellone, Charlie Ward, Sophia Vinogradov. .
      View in: Publisher Site   Mentions:
    20. In people with ultra high risk symptoms, risk of transition to psychotic disorders is highest in the first 2 years. Evid Based Ment Health. 2014 May; 17(2):39. Schlosser DA. PMID: 24591545.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. Schizophr Bull. 2015 Jan; 41(1):250-8. Fisher M, Loewy R, Carter C, Lee A, Ragland JD, Niendam T, Schlosser D, Pham L, Miskovich T, Vinogradov S. PMID: 24444862.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    22. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. Annu Rev Clin Psychol. 2013; 9:435-63. Fisher M, Loewy R, Hardy K, Schlosser D, Vinogradov S. PMID: 23297786.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    23. Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis. Adolesc Psychiatry (Hilversum). 2012 Apr; 2(2):163-171. Schlosser DA, Pearson R, Perez VB, Loewy RL. PMID: 23125956.
      View in: PubMed   Mentions:
    24. A randomized trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Interv Psychiatry. 2012 Aug; 6(3):283-91. Schlosser DA, Miklowitz DJ, O'Brien MP, De Silva SD, Zinberg JL, Cannon TD. PMID: 22182667.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    25. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr Bull. 2012 Nov; 38(6):1225-33. Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, Bearden CE, Cannon TD. PMID: 21825282.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    26. Predicting the longitudinal effects of the family environment on prodromal symptoms and functioning in patients at-risk for psychosis. Schizophr Res. 2010 May; 118(1-3):69-75. Schlosser DA, Zinberg JL, Loewy RL, Casey-Cannon S, O'Brien MP, Bearden CE, Vinogradov S, Cannon TD. PMID: 20171848.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    27. Multifamily group treatment for schizophrenia. Int J Group Psychother. 2009 Jul; 59(3):435-40. Stuart BK, Schlosser DA. PMID: 19548790.
      View in: PubMed   Mentions:    Fields:    
    Danielle's Networks
    Concepts (94)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (18)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑